EP1003743A4 - Piperidines 3,3-disubstituees utilisees comme modulateurs de l'activite de recepteurs de chemokines - Google Patents

Piperidines 3,3-disubstituees utilisees comme modulateurs de l'activite de recepteurs de chemokines

Info

Publication number
EP1003743A4
EP1003743A4 EP98905975A EP98905975A EP1003743A4 EP 1003743 A4 EP1003743 A4 EP 1003743A4 EP 98905975 A EP98905975 A EP 98905975A EP 98905975 A EP98905975 A EP 98905975A EP 1003743 A4 EP1003743 A4 EP 1003743A4
Authority
EP
European Patent Office
Prior art keywords
modulators
chemokine receptor
receptor activity
disubstituted piperidines
piperidines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98905975A
Other languages
German (de)
English (en)
Other versions
EP1003743A1 (fr
Inventor
Malcolm Maccoss
Sander G Mills
Timothy Harrison
Christopher John Swain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9707490.0A external-priority patent/GB9707490D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1003743A1 publication Critical patent/EP1003743A1/fr
Publication of EP1003743A4 publication Critical patent/EP1003743A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
EP98905975A 1997-01-21 1998-01-20 Piperidines 3,3-disubstituees utilisees comme modulateurs de l'activite de recepteurs de chemokines Withdrawn EP1003743A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3585497P 1997-01-21 1997-01-21
US35854P 1997-01-21
GBGB9707490.0A GB9707490D0 (en) 1997-04-14 1997-04-14 3,3-Disubstituted piperidines as modulators of chemokine receptor activity
GB9707490 1997-04-14
PCT/US1998/001101 WO1998031364A1 (fr) 1997-01-21 1998-01-20 Piperidines 3,3-disubstituees utilisees comme modulateurs de l'activite de recepteurs de chemokines

Publications (2)

Publication Number Publication Date
EP1003743A1 EP1003743A1 (fr) 2000-05-31
EP1003743A4 true EP1003743A4 (fr) 2001-04-11

Family

ID=26311372

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98905975A Withdrawn EP1003743A4 (fr) 1997-01-21 1998-01-20 Piperidines 3,3-disubstituees utilisees comme modulateurs de l'activite de recepteurs de chemokines

Country Status (5)

Country Link
EP (1) EP1003743A4 (fr)
JP (1) JP2001508798A (fr)
AU (1) AU6133098A (fr)
CA (1) CA2278309A1 (fr)
WO (1) WO1998031364A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
SK285729B6 (sk) 1997-11-18 2007-07-06 Teijin Pharma Limited Zlúčenina derivátov cyklických amínov a jej použitie
WO2000035876A1 (fr) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Heterocycles 2-substitues-4-azote utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
US6492400B1 (en) 1998-12-18 2002-12-10 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6486180B1 (en) 1998-12-18 2002-11-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6331545B1 (en) 1998-12-18 2001-12-18 Soo S. Ko Heterocycyclic piperidines as modulators of chemokine receptor activity
DE69926806D1 (de) 1998-12-18 2005-09-22 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
EP1013276A1 (fr) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalcanes comme modulateurs de CCR5
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
CA2360672A1 (fr) * 1999-01-29 2000-08-03 Wayne W. Hancock Methodes de prevention des rejets de greffes et des lesions par ischemie/reperfusion
AU4796700A (en) * 1999-05-13 2000-12-05 Dupont Pharmaceuticals Research Laboratories, Inc. Ureido-substituted cyclic amine derivatives and their use as drug
CA2373942A1 (fr) 1999-05-18 2000-11-23 Teijin Limited Remedes ou prophylactase contre les maladies associees a des chimiokines
US6358979B1 (en) 1999-06-11 2002-03-19 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
EP1192133B1 (fr) * 1999-06-11 2006-11-02 Merck & Co., Inc. Modulateurs n-cyclopentyliques de l'activite du recepteur de la chimiokine
WO2000076513A1 (fr) 1999-06-11 2000-12-21 Merck & Co., Inc. Modulateurs cyclopentyliques de l'activite du recepteur de la chimiokine
WO2000076512A1 (fr) 1999-06-11 2000-12-21 Merck & Co., Inc. Modulateurs cyclopentyliques de l'activite du recepteur de la chimiokine
WO2000076514A1 (fr) 1999-06-11 2000-12-21 Merck & Co., Inc. Modulateurs de cyclopentyle de l'activite du recepteur de chimiokine
WO2000076511A1 (fr) 1999-06-11 2000-12-21 Merck & Co., Inc. Modulateurs cyclopentyle de l'activite des recepteurs de la chimiokine
WO2000076973A1 (fr) 1999-06-11 2000-12-21 Merck & Co., Inc. Modulateurs n-cyclopentyliques de l'activite du recepteur de la chimiokine
CA2378499A1 (fr) 1999-08-04 2001-02-15 Teijin Limited Antagonistes d'amine cyclique ccr3
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
US6897234B2 (en) 1999-12-17 2005-05-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6410566B1 (en) 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
JP2004517805A (ja) 2000-06-30 2004-06-17 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体活性調節剤としてのｎ−ウレイドヘテロシクロアルキル−ピペリジン
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
CZ20032531A3 (cs) 2001-03-19 2004-01-14 Ono Pharmaceutical Co., Ltd. Derivát triazaspiro[5.5]undekanu a farmaceutická kompozice obsahující tento derivát jako účinnou složku
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
CA2497903A1 (fr) * 2002-09-18 2004-04-01 Ono Pharmaceutical Co., Ltd. Derives triazaspiro[5.5]undecanes et medicaments les contenant en tant que principe actif
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
SE0302755D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel compounds
SE0303090D0 (sv) 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303280D0 (sv) * 2003-12-05 2003-12-05 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
EP1723178A4 (fr) 2004-03-12 2007-12-12 Human Genome Sciences Inc Recepteur humain (ccr5) hdgnr10 de chimiokine de la proteine g
CL2008001810A1 (es) * 2007-06-20 2008-12-26 Glaxo Group Ltd Compuestos derivados de espiroindolinas, moduladores de receptores de quimiocinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar aterosclerosis, dolor inflamatorio, influenza, sindrome metabolico, entre otras enfermedades.
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2018106945A1 (fr) 2016-12-07 2018-06-14 Progenity Inc. Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
EP3554541B1 (fr) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec une chimoikine/un inhibiteur du récepteur de chimiokine
EP3883635A1 (fr) 2018-11-19 2021-09-29 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie au moyen d'une biothérapie
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
AU2021222441A1 (en) 2020-02-19 2022-09-22 Ichilov Tech Ltd. Improved antidepressant therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011090A2 (fr) * 1996-09-16 1998-03-19 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
US5589489A (en) * 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
EP0714891A1 (fr) * 1994-11-22 1996-06-05 Eli Lilly And Company Antagonistes hétérocycliques de récepteurs de la tachykinine
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011090A2 (fr) * 1996-09-16 1998-03-19 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9831364A1 *

Also Published As

Publication number Publication date
EP1003743A1 (fr) 2000-05-31
CA2278309A1 (fr) 1998-07-23
AU6133098A (en) 1998-08-07
WO1998031364A1 (fr) 1998-07-23
JP2001508798A (ja) 2001-07-03

Similar Documents

Publication Publication Date Title
EP1003743A4 (fr) Piperidines 3,3-disubstituees utilisees comme modulateurs de l'activite de recepteurs de chemokines
EP1171122A4 (fr) Pyrrolidines modulateurs de l'activite du recepteur de chimiokine
AU2056800A (en) Heterocyclic piperidines as modulators of chemokine receptor activity
EP1140086A4 (fr) N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
AU2482100A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126700A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1558253A4 (fr) Modulateur piperidinyl-alpha-aminoamide de l'activite de recepteurs de la chimiokine
AU2056700A (en) 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
EP1003514A4 (fr) Amines cycliques modulant l'activite des recepteurs de chimiokines
AU5812498A (en) Substituted aminoquinolines as modulators of chemokine receptor activity
AU5522498A (en) Substituted aryl piperazines as modulators of chemokine receptor activity
DK0870003T3 (da) Hydrobehandlingskatalysator: sammensætning, fremstilling og anvendelse deraf
AU4074200A (en) Pyrrolidine modulators of chemokine receptor activity
EP1558250A4 (fr) Modulateurs gamma-aminoamides de l'activite de recepteur de chimiokine
DE69840882D1 (de) Cationische Electrotauchlackzusammensetzung
EP1009405A4 (fr) Modulateurs de pyrrolidine et de piperidine de l'activite du recepteur de chemokine
EP1558599A4 (fr) Modulateurs d'heteroarylpiperidine de l'activite des recepteurs de la chimiokine
DE59811578D1 (de) Katalysatorzusammensetzung
MX199501B (es) Sintesis asimetrica de (-)6-cloro-4-ciclopropiletinil-4-trifluorometil-1,4-dihidro-2h-3,1-benzoxazin-2-ona
AU4201200A (en) Pyrrolidine modulators of chemokine receptor activity
AU1201401A (en) Benzylcycloalkyl amines as modulators of chemokine receptor activity
AU3386400A (en) 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
AU3389300A (en) Pyrrolidine modulators of chemokine receptor activity
DK1021541T3 (da) Aminoterminalt trunkeret MCP-2 som chemokinantagonister
FR2768544B1 (fr) Procede de detection d'activite vocale

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010228

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 211/06 A, 7C 07D 211/22 B, 7C 07D 221/20 B, 7C 07D 401/06 B, 7C 07D 401/14 B, 7A 61K 31/44 B, 7A 61K 31/445 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030801